BrightSpring Reiterates 2027 Profit Growth Goal And Says It Could Do '400 Of EBITDA' In Deals

The home-health and pharmacy company still expects at least 15% to 20% organic adjusted EBITDA growth in 2027, now off a larger 2026 base.

Share
BrightSpring Reiterates 2027 Profit Growth Goal And Says It Could Do '400 Of EBITDA' In Deals

BrightSpring Health Services still expects at least 15% to 20% organic adjusted EBITDA growth in 2027, CEO Jon Rousseau said on the company's third-quarter earnings call Friday, and the company is leaning toward somewhat larger acquisitions. BrightSpring, which provides pharmacy and in-person home and community care to medically complex patients, reported $228 million of adjusted EBITDA for the quarter, up 42% from a year earlier.

A bigger base for 2027 growth

Rousseau said the company reiterates the 15% to 20% target from its analyst day, "however, now off of a significantly larger EBITDA base in 2026." He expects similar year-over-year growth rates in each quarter of next year.

CFO Jen Phipps added that second-half 2027 growth should run a little higher than the first half, in line with normal seasonal patterns. She said 2026 adjusted EBITDA is now expected at $850 million to $860 million, which is 37.6% to 39.3% growth over 2025. Full 2027 guidance is due when the company reports fourth-quarter results in February.

A Mizuho analyst asked whether that even cadence means limited-distribution drugs, rather than generics, drive growth. Rousseau said the company would stick to its prepared remarks and pointed to a "plethora of growth drivers" across service lines.

Deal appetite grows with the balance sheet

Asked by a UBS analyst about acquisitions, now that leverage sits below the company's 2.5 times target, Rousseau said BrightSpring has leaned toward slightly larger deals than small tuck-ins, though still around "20-ish of EBITDA or below." He said: "we could do 400 of EBITDA and M&A tomorrow if we wanted to," adding he was not saying it "tongue-in-cheek" and that the company is "extremely intentional" in diligence.

Rousseau said BrightSpring has not entertained deals in partnership with anyone else and does not expect to. Leverage ended September at 1.79 times, down from 2.15 times at the end of June, and Phipps said the company is evaluating its capital structure heading into 2027 to support growth plans.

The quarter behind the outlook

Revenue rose 26% to $4.2 billion, with adjusted earnings of $0.54 per share. Pharmacy Solutions revenue was $3.7 billion, while Provider Services revenue of $481 million grew 31%. Specialty and infusion scripts grew 29%.

Operating cash flow was $204 million in the quarter, and management projects at least $700 million for the year, excluding the community living sale. BrightSpring shares were up 12.54% at $67.77 in Friday morning trading.

Management will lay out full 2027 guidance when it reports fourth-quarter results in February.

Sources

More on BrightSpring Health Services

All BrightSpring Health Services (BTSG) coverage →